Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
Background. Antithrombotic therapy in chronic lymphocytic leukemia (CLL) patients is challenging, as this category of patients is initially characterized by high risk of hemorrhagic complications. The use of ibrutinib influencing the platelet function constitutes an additional bleeding risk. A cruci...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2019-09-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: |
http://bloodjournal.ru/wp-content/uploads/2019/09/11-1.pdf
|
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|